• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

AAO 2023: RXSight offers poster, product updates in San Francisco

Article

News

RxSight Inc announced educational opportunities and product updates at the American Academy of Ophthalmology's 127th Annual Meeting in San Francisco, California.

RXSight made several announcements at AAO 2023 in San Francisco. (Image courtesy of Adobe Stock)

RXSight made several announcements at AAO 2023 in San Francisco. (Image courtesy of Adobe Stock)

RxSight Inc today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting San Francisco.

Accoring to a news release, these include 3 scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations.

At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens (LAL) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision.

Steven Slade, MD, of Houston-based Slade & Baker Vision provided a report on clinical results using the LAL+, a new addition to the LAL family that will become available in the first quarter of 2024.

According to the company, the LAL+ has a built-in optical feature that is

designed to further extend the depth of focus before light treatments, while preserving the high-quality vision of the LAL already familiar to customers and patients.

RxSight’s reconfigured Light Delivery Device (LDD) will also be on display during AAO. While providing the same functionality and outcomes as the standard LDD, this compact model has a smaller footprint to address global practice space constraints.

Related Videos
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.